Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer

被引:13
作者
Chang, Eugene Y.
Smith, Christina A.
Corless, Christopher L.
Thomas, Charles R., Jr.
Hunter, John G.
Jobe, Blair A.
机构
[1] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97239 USA
关键词
esophageal cancer; neoadjuvant chemoradiation; pathologic complete response; staging;
D O I
10.1016/j.amjsurg.2007.01.002
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Although a substantial proportion of patients undergoing neoadjuvant chemoradiation for invasive esophageal cancer develop a pathologic complete response (pCR), these patients nonetheless have a poor 5-year survival rate. We hypothesized that routine pathologic examination fails to identify some residual cancer. Methods: Patients undergoing esophagectomy for cancer at 2 tertiary care centers were identified. Archived tumor blocks were retrieved for patients with pCR, sectioned at 50-mu m intervals and reexamined for residual cancer. Results: Seventy patients underwent neoadjuvant chemoradiation. Tumor blocks were available for 23 of 2 6 complete responders. A total of 159 blocks were reexamined. One patient was found to have a possible focus of residual invasive adenocarcinoma versus high-grade dysplasia. The remaining 22 patients had no residual disease. Conclusions: A more aggressive examination protocol for postchemoradiation esophagectomy specimens may not result in significant upstaging. Inadequate pathologic examination is likely not a major factor in the suboptimal survival in patients with pCR. (c) 2007 Excerpta Medica Inc. All rights reserved.
引用
收藏
页码:614 / 617
页数:4
相关论文
共 35 条
[1]   Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival [J].
Berger, AC ;
Farma, J ;
Scott, WJ ;
Freedman, G ;
Weiner, L ;
Cheng, JD ;
Wang, H ;
Goldberg, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4330-4337
[2]  
CLAYTON F, 1993, CANCER-AM CANCER SOC, V71, P1780, DOI 10.1002/1097-0142(19930301)71:5<1780::AID-CNCR2820710512>3.0.CO
[3]  
2-2
[4]  
Czerniecki BJ, 1999, CANCER, V85, P1098, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1098::AID-CNCR13>3.3.CO
[5]  
2-E
[6]  
Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO
[7]  
2-Z
[8]   PROGNOSTIC-SIGNIFICANCE OF BREAST-CANCER AXILLARY LYMPH-NODE MICROMETASTASES ASSESSED BY 2 SPECIAL TECHNIQUES - REEVALUATION WITH LONGER FOLLOW-UP [J].
DEMASCAREL, I ;
BONICHON, F ;
COINDRE, JM ;
TROJANI, M .
BRITISH JOURNAL OF CANCER, 1992, 66 (03) :523-527
[9]   Tumor response to induction chemoradiation: influence on survival after esophagectomy [J].
Donington, JS ;
Miller, DL ;
Allen, MS ;
Deschamps, C ;
Nichols, FC .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 24 (04) :631-636
[10]   Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer [J].
Forastiere, AA ;
Goepfert, H ;
Maor, M ;
Pajak, TF ;
Weber, R ;
Morrison, W ;
Glisson, B ;
Trotti, A ;
Ridge, JA ;
Chao, C ;
Peters, G ;
Lee, DJ ;
Leaf, A ;
Ensley, J ;
Cooper, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2091-2098